Tofacitinib Trial Prompts FDA Review of Adverse Effects

A required postmarketing clinical trial of tofacitinib (Xeljanz, Xeljanz XR) in the treatment of rheumatoid arthritis found an increased risk of pulmonary embolism and death when patients were treated with 10 mg twice daily compared with the currently approved 5 mg twice daily dose.NPs are encouraged to follow tofacitinib's dosing guidelines when treating rheumatoid arthritis.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research